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RESULTS: Varying the compliance rates between 95% and
70% resulted in the average annual drug costs per patient
ranging between $609 and $911 (49.6% difference). Sensi-
tivity analyses of published drug-cost ranges between $400
and $821 for NVF and $800 and $1642 for VF caused av-
erage annual drug costs to vary by 51.8%. Reexamining the
94% compliance assumptions of a recently published report
found that the $1.1 billion estimate for treating HIV/AIDS
in Africa may underestimate costs by more than 28%.
CONCLUSION: Given that studies have demonstrated a
high degree of variability in HIV/AIDS drug compliance
in Africa, future cost studies should examine the impact
of varying compliance rates on their results.
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OBJECTIVE: To outline results of a retrospective analysis
of patient charts at three dermatology clinics in the Neth-
erlands for treatment of external genital warts (EGWs).
METHODS: Patient records with a principal treatment
of EGW were identified. A total of 530 completed epi-
sodes of care for EGWs were analyzed. A (completed) ep-
isode of care was defined as a sequence of visits resulting
in either wart clearance or patient referral to additional
care, typically surgery.
RESULTS: Over 80% of the patients were initially treated
with monotherapy, and podophyllin and cryotherapy were
the principal initial therapy choices. Only 61.7% of males
and 68.4% of females completed an episode of care with
their initial choice of monotherapy. The average total cost of
an episode of care was DFL487.76 and DFL644.13 for males
and females respectively. The cost of achieving a successful
outcome or episode of care (taking into account the propor-
tion of patients with complete and incomplete episode of
care) was DFL872.50 for males and DFL1,068.91 for fe-
males. The cost of completing an episode of care for those
who initiated on podophyllin, taking into account therapy
switching, was DFL451.40 for males (DFL851.48 for fe-
males) compared with DFL426.63 for males initiated on
cryotherapy (DFL372.94 for females) and DFL780.56 for
males initiated on podophyllotoxin (DFL518.57 for females).
CONCLUSION: Podophyllin, although no longer recom-
mended in treatment guidelines, is one of the most fre-
quently used therapies. Costs of treating EGWs are sig-
nificantly impacted by the need to switch.
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OBJECTIVE: To estimate the cost-utility of universal vac-
cination of infants with four doses of a combined 9-valent
conjugated pneumococcal/6-valent outer membrane vesi-
cle meningococcal B/C vaccine in the Netherlands, from a
societal perspective.
METHODS: A decision analysis model is employed to
estimate the health outcomes and costs of the vaccination
program. Data were derived from the Netherlands Refer-
ence Laboratory for Bacterial Meningitis, PRISMANT
Healthcare, national and international literature, and an
expert panel. Direct costs and productivity costs (friction
cost method) are considered. Future costs and QALYs
are discounted at 4%. Cost-utility is expressed as net
costs (in 1998 €) per QALY gained. For the baseline, a
vaccine dose price of €20 and vaccine dose administra-
tion cost of €5 are assumed. The study fully corresponds
with the Dutch guidelines for pharmacoeconomic re-
search.
RESULTS: The vaccination program is estimated to cost
ED18,741,600, to prevent 27 deaths and 16 severe se-
quelae (e.g. seizures, spasticity, and mental retardation),
and to avoid €7,546,600 in expenses per year. It would
render 735 QALYs per year at a cost-utility of €15,200
per QALY. The break-even dose price of the vaccine is
€5.7. These results are sensitive to the vaccine price, the
vaccine effectiveness, and the vaccine coverage against
other meningococcal serosubtypes and pneumococcal se-
rotypes. Excluding the productivity costs has a limited in-
fluence.
CONCLUSIONS: The combination vaccine has not only
a favourable cost-utility ratio when compared to other
vaccines, but also averts a significant number of deaths
and severe sequelae. Therefore it would be a promising
candidate for national immunization programs.
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Clinical trial cost modeling is rarely done, but early pro-
tocol development and cost identification may reduce the
uncertainty surrounding return on investment for thera-
pies such as a new pulmonary TB drug.
OBJECTIVE: To develop a Phase III trial protocol for a po-
tential new pulmonary TB drug and estimate the trial costs.
METHODS: We developed a trial protocol based on the
study design submitted to the Food and Drug Administra-
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tion (FDA) for rifapentine and the Good Clinical Practice
(GCP) standards of the International Conference on Har-
monization of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH). Clinical trial ex-
perts reviewed the protocol and costs were assessed based
on the Resource Based Relative Value Scale (RBRVS), ex-
pert opinion, and published prices for materials and ser-
vices. We constructed a model that summarized costs per
patient, per trial site, and per trial to implement the proto-
col. Entering the number of patients to be assessed, num-
ber of trial sites, number of trials, and anticipated drop out
rates generated estimated costs. The model calculated the
cost for all patients to complete the trial, costs associated
with screening patients who drop out immediately, and
savings that may be realized from patients dropping out
during the trial. These figures generated lower and upper
trial cost estimates. A 15% drop out rate at screening and
a 15% drop out rate during the trial was assumed.
RESULTS: For 850 to 1,000 patients to complete a Phase
III trial, 1,176 patients will need to be screened. The esti-
mated total cost (2000 US dollars) is between $22.3 mil-
lion and $22.6 million.
CONCLUSIONS: A Phase III clinical trial for a new pul-
monary TB drug will cost between $22.3 million and
$22.6 million, assuming a drop out rate no greater than
15% at screening and 15% over the course of the trial.
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OBJECTIVE: To assess the cost-effectiveness of Aldara
(Imiquimod) 5% topical cream versus other therapies for
the management of external genital warts (EGWs) in a
Dutch treatment environment.
METHODS: An economic model is presented that uti-
lizes a two-stage therapy sequence. Choice of initial and
subsequent therapy was based on the results of a recently
completed chart review of three dermatology clinics in
the Netherlands. This chart review provided valuable
guidance regarding treatment switching, resources used
(i.e. average number of patient visits) and costs associ-
ated with the management of EGWs. Sustained clearance
rates were incorporated into the economic model based
on published literature of key clinical trial results. Cost-
ing was based on nationally available cost estimates for
the Netherlands as costs based on chart reviews were site
specific and hence were not appropriate for use.
RESULTS: Estimated average costs per successful clearance
for Aldara plus cryotherapy were 1,128 DFL (€512) com-
pared with 1,455 DFL (€660) for the next most cost-effec-
tive therapy sequence—Condyline (first line) plus cryother-
apy (second line). In terms achieving the therapeutic target
of 50% clearance, only sequences in which Aldara was used
as first line therapy achieved this.
CONCLUSION: The results of the cost-effectiveness
analysis demonstrated that Aldara (as first line therapy)
plus cryotherapy (second line) was the most cost-effective
therapy sequence in the Netherlands.
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OBJECTIVE: To estimate costs and benefits of a preven-
tive influenza vaccination in a group of employees of Snam-
progetti (an Eni-group company), to define a scheme of
cost-benefit analysis to be used for other strategies of vacci-
nation and in other contexts.
METHODS: In an observational study conducted from
October 1999 to June 2000, 153 employees (about 10%
of the whole staff of Snamprogetti) voluntarily received
the vaccine, and were compared to 153 non-vaccinated
employees working in the same context and matched for
age and gender. The outcome was evaluated by checking
absentee records from the personnel department and de-
termining the causes, including influenza. Costs and ben-
efits of the influenza vaccination from the Snamprogetti
point of view were subsequently calculated.
RESULTS: The influenza vaccination strategy reduced
absence from work by 77% and has decreased the loss of
working days by 82%. The relationship between the ben-
efits of the vaccination strategy (less working days lost)
and its cost was 12.12. Convenience also becomes evi-
dent following sensitivity analysis, which considered the
mean cost of a working day for the employees enrolled,
and showed that the cost-benefit ratio was 9.45.
CONCLUSIONS: The results of this study suggest that
implementation of an influenza vaccination strategy in
Snamprogetti was cost effective. The cost-benefit analysis
used in this study could also be used for other vaccina-
tion strategies and in other contexts.
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OBJECTIVES: Influenza is a major cause of illness, pro-
ductivity loss, and work absenteeism among healthy work-
ing adults aged between 25 and 64 years. This group is not
